MedCity News August 2, 2022
Decentralized clinical trial approaches helped the pharma industry navigate through Covid-19. Now it is becoming increasingly clear that there’s a need for a hybrid approach to decentralized clinical trials that considers the perspectives of patients and the impact to clinical trial sites.
Even before Covid-19 disrupted the traditional model for clinical trials, researchers were harnessing the power of technology to make trials more accessible and improve data collection.
The movement had coalesced under the banner of decentralized clinical trials, or DCTs, which leverage technology and other non-traditional approaches to monitor patients and gather data without limits on geography. Another envisioned benefit included the ability to recruit a broader patient population.
The pandemic accelerated the adoption of DCTs, but it also...
Today's Sponsors
Today's Sponsor